Methylene Blue · injectable solution
Diagnostic Dye
Approved uses
Drug-induced methemoglobinemia (systemic, not an ocular use)
0.1 to 0.2 mL/kg of the 1% solution IV, injected very slowly over several minutes
Contraindications
- Women who are or may become pregnant (an association exists between use in amniocentesis and atresia of the ileum and jejunum, ileal occlusions, and other adverse effects in the neonate)
- Intraspinal or subcutaneous injection
- Known hypersensitivity to methylene blue
1% injection (10 mg/mL), 2 mL single-dose prefilled syringes, cartons of five.
Low concentrations reduce methemoglobin back to hemoglobin, while high concentrations oxidize ferrous iron to ferric and generate methemoglobin; metabolism is to leukomethylene blue, excreted mainly in urine. It is also a potent monoamine oxidase inhibitor, which is the basis of the serotonin toxicity risk.
Warnings & Precautions
- Serotonin syndrome: Boxed warning. May cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs. Avoid concomitant use with selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors.
- Serotonin toxicity: Methylene blue is a potent monoamine oxidase inhibitor (MAOI) and may interact with any drug that acts as a serotonin reuptake inhibitor (SRI), including tricyclic antidepressants, norepinephrine-dopamine reuptake inhibitors, triptans and ergot alkaloids; such combinations may have the consequence of potentially fatal serotonin toxicity. It should not be co-administered with any SRI, and if methylene blue is judged to be indicated, SRIs must be ceased prior to treatment.
- Paradoxical methemoglobinemia and hemolysis: Methylene blue should be avoided in patients with G6PD deficiency.
- Additional methemoglobin: Inject intravenously very slowly over a period of several minutes to prevent local high concentration from producing additional methemoglobin. Do not exceed recommended dosage. Large intravenous doses produce nausea, abdominal and precordial pain, dizziness, headache, profuse sweating, mental confusion, and the formation of methemoglobin.
- Renal failure: Use with caution in patients with severe renal impairment.
- Not for subcutaneous or intrathecal injection: Methylene blue should not be given by subcutaneous or intrathecal injection.
Common Side Effects
Large intravenous doses produce nausea, abdominal and precordial pain, dizziness, headache, profuse sweating, mental confusion, and the formation of methemoglobin. Serotonin toxicity is characterized by neuromuscular hyperactivity (tremor, clonus, myoclonus, and hyperreflexia, and, in the advanced stage, pyramidal rigidity), autonomic hyperactivity (diaphoresis, fever, tachycardia, tachypnea, and mydriasis), and altered mental status (agitation, excitement, and, in the advanced stage, confusion).
Pregnancy: Contraindicated. Pregnancy Category X; epidemiologic evidence exists that methylene blue is a teratogen. An association exists between the use of methylene blue in amniocentesis and atresia of the ileum and jejunum, ileal occlusions, and other adverse effects in the neonate. It should not be administered to pregnant women during amniocentesis.
Lactation: Not addressed in this label.
Not addressed in this label.